Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Study of HER2+ Breast Cancer Patients With Active Refractory Brain Metastases Treated With Afatinib in Combination With T-DM1 vs. T-DM1 Alone

NCT04158947 is registered in ClinicalTrials.gov with xuexin he as lead sponsor.

NCT NCT04158947
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04158947 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Study of HER2+ Breast Cancer Patients With Active Refractory Brain Metastases Treated With Afatinib in Combination With T-DM1 vs. T-DM1 Alone
Lead sponsor
xuexin he
Phase
Phase 2
Overall status
Unknown status
Start date
May 10, 2020
Completion date
March 31, 2024
Enrollment
130 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

brain metastases, her2-positive breast cancer